The core premise in this blog is: Federal Meaningful Use (MU)
requirements are well-intended, but like a teacher who "teaches to the
test", the federal MU program created a very complicated system that might
pass the test of MU, but is not producing meaningful results for
patients and clinicians. As reported in MedScape, the first formal study
of this kind was published in the April 2014 issue of JAMA Internal Medicine, which shows no correlation between quality of care and MU
adherence. The study validates what common sense told many of us for the
last few years.
MU Stage 1 was a jump-start for EMR adoption in the industry. That's a
good thing, I suppose, although MU also created a false market for
mediocre products. It's time to put an end to the federal MU
program, eliminate the costly administrative overhead of MU, remove the
government subsidies that also create perverse incentives, and let
"survival of the fittest" play a bigger part in the process.
Let the fruits of EMR utilization go to the organizations that commit, on
their own and without government incentives, to maximizing the value of their
EMR investments towards quality improvement, cost reduction, and clinical
efficiency.
When I arrived at Northwestern Medicine in 2005, it was clear very
early that our EMRs (Epic and Cerner) were not being used in a meaningful
way; this was several years before any broad discussion of MU in the
industry. Many Northwestern physicians were still using paper charts
alongside the EMR, thus creating a fragmented and dangerous medical record for
patients.
Using the log and audit files in Epic and Cerner, we created an
"EMR Utilization Dashboard" for each physician that also rolled up to
the organizational level. The data was revealing. Outside of
General Internal Medicine and a few other spotty areas, the medication list was
not being used. The problem list was not being used. Order entry for
medications, prescriptions and tests was not being used. Templates for
documentation efficiency were not being used. Clinical alerts for best
practices were not being used. Many patient encounters were not being
documented in the EMR, indicating the continued use of paper records. In short,
these very expensive EMRs were being used only occasionally as expensive
word processors and dictation systems.
With input from all physicians, Drs. David Liebovitz, Phil Roemer,
Gary Martin and I decided to develop a simple document, describing the
core principles of EMR utilization. Sarah Miller, my director of
clinical applications, also played a huge part in this project. We declared
that it had to be constrained to a single page, normal spacing and font, and
that we had to be data driven. It was a big success. Over the next
two years, our rudimentary EMR Utilization Dashboard showed steady and
significant improvement. I showed the dashboard and the
core principles to John Glaser (then at Partners) while we were both
speaking at a conference in Victoria, British Columbia. A few years
later, when John went to ONC to support David Blumenthal, John took the
influence of those core principles and dashboard with him. I'm not
exactly sure what role the dashboard and those principles played in seeding the
federal MU program, but I suspect they had some degree of influence. By
the way, we (Northwestern) offered to give the code and dashboard to the EMR
vendors so that all clients could benefit, but the vendors declined. We
shared them instead on the Users Groups' web sites.
Below are the simple but effective "Core Principles of EMR Utilization" that we developed and
that played a huge part in the progressive value of Cerner and Epic on the
Northwestern campus, and laid the foundation for a relatively easy
qualification of Northwestern under the federal MU program.
Core Principles of EMR Utilization
Encounters
· All patient
appointments/visits are to be documented in the EHR as an encounter.
· Visit encounters
should by closed by the attending physician within 48 hours of the patient
visit.
Medications
· All medication
prescriptions and refills must be documented in the EHR, including those
ordered in a telephone encounter.
· Medications are to
be reviewed at every patient encounter, in accordance with the individual
specialty’s standard of care.
· Every effort
should be made to maintain a valid and complete list of patients’ current
medications in the EHR, including end dates, discontinuing medications no
longer being taken, and removing duplicate medication entries.
Problem Lists
· All chronic,
persistent patient diagnoses or complaints should be documented on the Problem
List in the EHR, with the exception of highly sensitive diagnoses such as those
associated with mental health care.
· Problems should be
documented using the most specific term applicable to the problem, e.g. mild
intermittent asthma vs. asthma.
· The Problem list
should be reviewed and updated at every patient encounter, in accordance with
the individual specialty’s standard of care, and problems not currently
clinically relevant should be filed to history and marked as resolved.
Allergies
· Allergy lists must
be actively maintained for validity and completeness for all patients,
including marking as reviewed when no new allergies are reported. The allergy
list must be reviewed during any encounter in which a medication is ordered.
Orders
· All patient orders
must be documented in the EHR.
Progress Notes
· All patient
encounters should have an accompanied progress note that appropriately
documents the history, physical, and decision-making in a way that is succinct
and minimizes redundant content.
· If dictating,
notes must include the patient’s name and medical record number, the date of
the encounter, and the attending physician’s name to ensure timely
documentation.
In Basket
· Patient results
and messages should be reviewed within 72 hours of receipt and In Basket
coverage should be assigned when clinicians are unable to respond within that
time frame.
In the early days of EMRs, the pioneers like Intermountain, Vanderbilt,
Duke, and Partners differentiated themselves by developing their own proprietary
EMRs and then using them in a meaningful way, without any financial incentive
except their own to do so. Meaningful
Use Stage 1 served a valuable purpose-- it jump-started the adoption of commercially
supported EMRs in an industry that needed jump-starting. Maybe we should cancel Stage 2 and Stage 3,
spend some of that money on to seed true innovation (think DARPA for healthcare), and let survival of the
fittest play a role in deciding which organizations will utilize their EMRs,
and subsequent data, most effectively to improve healthcare.
No comments:
Post a Comment